1. Home
  2. SMHI vs CHRS Comparison

SMHI vs CHRS Comparison

Compare SMHI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEACOR Marine Holdings Inc.

SMHI

SEACOR Marine Holdings Inc.

HOLD

Current Price

$6.68

Market Cap

179.4M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.35

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMHI
CHRS
Founded
1989
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.4M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SMHI
CHRS
Price
$6.68
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.02
AVG Volume (30 Days)
94.2K
961.1K
Earning Date
10-29-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.34
Revenue
$245,311,000.00
$277,728,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.81
$67.29
P/E Ratio
N/A
$1.01
Revenue Growth
N/A
152.07
52 Week Low
$3.63
$0.71
52 Week High
$7.88
$1.89

Technical Indicators

Market Signals
Indicator
SMHI
CHRS
Relative Strength Index (RSI) 44.14 51.35
Support Level $6.84 $1.31
Resistance Level $7.47 $1.41
Average True Range (ATR) 0.32 0.09
MACD -0.06 0.02
Stochastic Oscillator 18.95 68.93

Price Performance

Historical Comparison
SMHI
CHRS

About SMHI SEACOR Marine Holdings Inc.

Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: